{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T18:53:15.665993+00:00","company":{"ticker":"CLB","cik":1958086,"company_name":"Core Laboratories Inc. /DE/"},"pagination":{"limit":100,"returned":7,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"11bb91080c7130759f692bf9efa4240d57d87984","cik":1958086,"ticker":"CLB","company_name":"Core Laboratories Inc. /DE/","filed_at":"2026-04-29T23:59:59+00:00","payload":{"eps_text":"$0.02","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the first quarter of 2026","report_date":"2026-04-29","result_type":"reported_results","revenue_text":"$121.8 MILLION"},"claim":"Core Laboratories Inc. /DE/ reported the first quarter of 2026 results: revenue $121.8 MILLION, EPS $0.02.","evidence_excerpt":"results for the first quarter of 2026. \n\n--- EX-99.1 (EX-99.1) ---\n\nEX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB REPORTS FIRST QUARTER 2026 RESULTS: • REVENUE OF $121.8 MILLION, DOWN 12% SEQUENTIALLY AND FLAT YEAR-OVER-YEAR • OPERATING INCOME OF $1.9 MILLION; EX-ITEMS, $6.6 MILLION, DOWN 58% SEQUENTIALLY AND 44% YEAR-OVER-YEAR • GAAP LOSS PER SHARE OF","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-192018","anchor_url":"https://secwatch.observer/filing/0001193125-26-192018#claim-11bb91080c7130759f692bf9efa4240d57d87984","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1958086/000119312526192018/0001193125-26-192018-index.htm"},{"fact_type":"governance_change","fact_key":"6d098c5615aef0256e0a3163945203c6b095144e","cik":1958086,"ticker":"CLB","company_name":"Core Laboratories Inc. /DE/","filed_at":"2026-03-05T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2026-02-27","item_codes_triggered":["5.03"],"summary_text":"Lowered voting threshold for shareholder actions from 66-2/3% supermajority to simple majority"},"claim":"Core Laboratories Inc. /DE/: Lowered voting threshold for shareholder actions from 66-2/3% supermajority to simple majority (effective 2026-02-27).","evidence_excerpt":"the only change being to lower the voting threshold set forth in Section 2.11 for approval of certain shareholder actions, including the approval of merger and change in control transactions, from a 66-2/3% supermajority vote to a 50% plus one simple majority vote","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-093962","anchor_url":"https://secwatch.observer/filing/0001193125-26-093962#claim-6d098c5615aef0256e0a3163945203c6b095144e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1958086/000119312526093962/0001193125-26-093962-index.htm"},{"fact_type":"shareholder_vote","fact_key":"8b7091afd0661f7eec731cf7513d1dcba854fbb2","cik":1958086,"ticker":"CLB","company_name":"Core Laboratories Inc. /DE/","filed_at":"2024-05-10T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-05-08","outcome":"passed","proposal_text":"Amendment and restatement of the Company's 2020 Long-Term Incentive Plan to increase shares and extend term through May 8, 2034","proposal_type":"equity_plan","votes_abstain_text":"105,308","votes_against_text":"1,468,975","votes_for_text":"36,742,268"},"claim":"Core Laboratories Inc. /DE/ shareholders approved Amendment and restatement of the Company's 2020 Long-Term Incentive Plan to increase shares and extend term through May 8, 2034 at the 2024-05-08 meeting.","evidence_excerpt":"Proposal 4 – Approving the Amendment of the Company’s Long-Term Incentive Plan : The amendment and restatement of the Company’s 2020 Long-Term Incentive Plan, the principal purposes of which are to (i) increase the number of shares authorized thereunder and (ii) extend the term of such plan through May 8, 2034, was approved as follows: For Against Abstentions Broker Non-Votes 36,742,268 1,468,975 105,308 2,919,136","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-057934","anchor_url":"https://secwatch.observer/filing/0000950170-24-057934#claim-8b7091afd0661f7eec731cf7513d1dcba854fbb2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1958086/000095017024057934/0000950170-24-057934-index.htm"},{"fact_type":"shareholder_vote","fact_key":"a3812c5f24c3160ef6bb53c13be86257b3c2ead2","cik":1958086,"ticker":"CLB","company_name":"Core Laboratories Inc. /DE/","filed_at":"2024-05-10T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-05-08","outcome":"passed","proposal_text":"Advisory vote on compensation of named executive officers","proposal_type":"say_on_pay","votes_abstain_text":"82,370","votes_against_text":"1,822,497","votes_for_text":"36,411,684"},"claim":"Core Laboratories Inc. /DE/ shareholders approved Advisory vote on compensation of named executive officers at the 2024-05-08 meeting.","evidence_excerpt":"Proposal 3 – Approving the Compensation of the Company’s Executive Officers : An advisory vote on the compensation of the Company’s named executive officers was approved as follows: For Against Abstentions Broker Non-Votes 36,411,684 1,822,497 82,370 2,919,136","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-057934","anchor_url":"https://secwatch.observer/filing/0000950170-24-057934#claim-a3812c5f24c3160ef6bb53c13be86257b3c2ead2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1958086/000095017024057934/0000950170-24-057934-index.htm"},{"fact_type":"shareholder_vote","fact_key":"ea3a66120f3b35e8bc315472359796666617cb8d","cik":1958086,"ticker":"CLB","company_name":"Core Laboratories Inc. /DE/","filed_at":"2024-05-10T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-05-08","outcome":"passed","proposal_text":"Ratification of appointment of KPMG LLP as independent registered public accountant for the year ending December 31, 2024","proposal_type":"auditor_ratification","votes_abstain_text":"30,568","votes_against_text":"802,763","votes_for_text":"40,402,356"},"claim":"Core Laboratories Inc. /DE/ shareholders approved Ratification of appointment of KPMG LLP as independent registered public accountant for the year ending December 31, 2024 at the 2024-05-08 meeting.","evidence_excerpt":"Proposal 2 – Appointment of KPMG as Independent Registered Public Accountant : The ratification of the appointment of KPMG as the Company’s independent registered public accountant for the fiscal year ending December 31, 2024 was approved as follows: For Against Abstentions Broker Non-Votes 40,402,356 802,763 30,568 —","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-057934","anchor_url":"https://secwatch.observer/filing/0000950170-24-057934#claim-ea3a66120f3b35e8bc315472359796666617cb8d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1958086/000095017024057934/0000950170-24-057934-index.htm"},{"fact_type":"shareholder_vote","fact_key":"0047641c3df8589dce767ddcd2f49c6a7c22e296","cik":1958086,"ticker":"CLB","company_name":"Core Laboratories Inc. /DE/","filed_at":"2024-05-10T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-05-08","outcome":"passed","proposal_text":"Election of Class III Directors: Lawrence Bruno and Kwaku Temeng","proposal_type":"director_election","votes_abstain_text":null,"votes_against_text":"962,528; 5,285,742","votes_for_text":"37,354,023; 33,030,809"},"claim":"Core Laboratories Inc. /DE/ shareholders approved Election of Class III Directors: Lawrence Bruno and Kwaku Temeng at the 2024-05-08 meeting.","evidence_excerpt":"Proposal 1 – Election of Class III Directors : The election of each Class III director was approved as follows: Nominee For Withheld Broker Non-Votes Lawrence Bruno 37,354,023 962,528 2,919,136 Kwaku Temeng 33,030,809 5,285,742 2,919,136","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-057934","anchor_url":"https://secwatch.observer/filing/0000950170-24-057934#claim-0047641c3df8589dce767ddcd2f49c6a7c22e296","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1958086/000095017024057934/0000950170-24-057934-index.htm"},{"fact_type":"earnings_release","fact_key":"a158224bd8c10a0e60dde5bcefb0a69db2a37e17","cik":1958086,"ticker":"CLB","company_name":"Core Laboratories Inc. /DE/","filed_at":"2024-04-24T23:59:59+00:00","payload":{"eps_text":"$0.07","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first quarter of 2024","report_date":"2024-04-24","result_type":"reported_results","revenue_text":"$129,600,000"},"claim":"Core Laboratories Inc. /DE/ reported first quarter of 2024 results: revenue $129,600,000, EPS $0.07.","evidence_excerpt":"for the first quarter of 2024. \n\n--- EX-99.1 (EX-99.1) ---\n\nEX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB REPORTS FIRST QUARTER 2024 RESULTS: • FIRST QUARTER REVENUE OF $129.6 MILLION, UP MODESTLY SEQUENTIALLY AND YEAR-OVER-YEAR • FIRST QUARTER OPERATING INCOME OF $8.6 MILLION; EX-ITEMS, $14.9 MILLION, FLAT SEQUENTIALLY, UP 3% YEAR-OVER-YEAR • FIRST QUARTER","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-047646","anchor_url":"https://secwatch.observer/filing/0000950170-24-047646#claim-a158224bd8c10a0e60dde5bcefb0a69db2a37e17","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1958086/000095017024047646/0000950170-24-047646-index.htm"}]}